Social media

Deepali Suri, President of ICON Biotech, has been published in Pharmaceutical Executive. Her article draws on insights from 163 biotech leaders across North America, EMEA and APAC, supported by a supplementary survey o...

2026 will be a pivotal year for Europe’s HTA landscape. The Work Program forecasts: - \~50 JCAs for medicinal products - The first assessments of high risk medical devices - A fully operational HTA IT platform - More pre...

2026 will be a pivotal year for Europe’s HTA landscape. The Work Program forecasts: - ~50 JCAs for medicinal products - The first assessments of high risk medical devices - A fully operational HTA IT platform - More pred...

Human ADME studies are essential for understanding how investigational drugs are absorbed, distributed, metabolised and excreted. Yet traditional sampling—limited to plasma, urine and faeces- leaves a key blind spot: bil...

Human ADME studies are essential for understanding how investigational drugs are absorbed, distributed, metabolised and excreted. Yet traditional sampling—limited to plasma, urine and faeces- leaves a key blind spot: bil...

ICON will be attending the 20th #WRIB from 13–17 April at the Hyatt Regency Dallas. Meet ICON’s experts at booth \#31 to discuss how our PK, immunogenicity, biomarker, qPCR and flow cytometry expertise across small mole...

ICON will be attending the 20th #WRIB from 13–17 April at the Hyatt Regency Dallas. Meet ICON’s experts at booth #31 to discuss how our PK, immunogenicity, biomarker, qPCR and flow cytometry expertise across small molec...

Attending World Vaccine Congress? Join ICON’s Dinah Knotts-Keeterle on 1 April at 12:10 pm as she discusses on ‘AI and the future of vaccine studies from reaction to readiness’. Learn more. https://ow.ly/GzT350Yr8Y8

Join Thanh-Long Nguyen and other industry experts to discuss the latest developments in flow cytometry. This panel hosted by Bioanalysis Zone will explore how innovation is reshaping assay development and clinical trial ...

As the CRA role evolves, so do the opportunities for career progression. From In-House CRA to Clinical Trial Manager, Huseyin's journey highlights how roles are expanding and creating new opportunities for growth. Regi...

Patient led organisations are actively shaping scientific and regulatory pathways in ultra rare diseases. Our recent webinar captured powerful examples of how real people are accelerating progress to meet needs, deliver ...

Thank you to everyone who joined our Rare Disease Day webinar. The inspiring discussion highlighted the results of patients’ and parents’ relentless advocacy, including scientific breakthroughs and regulatory progress in...